Basilea Plans European Ceftobiprole Launches In Second-Quarter 2014
This article was originally published in The Pink Sheet Daily
The broad-spectrum cephalosporin, the first in a potential portfolio of hospital products for severe infections from the Swiss company, is nearing the market in the U.K. and Scandinavia.
You may also be interested in...
After seven years of trying to get ceftobiprole approved in the U.S., Basilea said it would not run further clinical trials without a partner. Plans for a launch in Europe remain on track.
Deal brings CHF75 million upfront plus welcome validation after Basilea's break-up with J&J on ceftobiprole.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.